OUR VISION
To become a global leader in innovative diagnostics and
therapeutics by
addressing key challenges in ophthalmic care.
We focus on establishing opened omics platforms for ophthalmology, investigating mechanisms of
eye
disorders, and developing innovative in vitro diagnostic and therapeutic products to
address
unmet needs
for the eye.
About Us
Founded in 2015, Seinda Biomedical Corp. is a specialized point-of-care
diagnostics company that brings together experts from the biomedical, pharmaceutical,
immunology,
and ophthalmology sectors to pioneer improved choices for eye care.
Seinda Pharmaceutical Corp.
acquired Seinda
Biomedical in 2020. As an innovation-driven enterprise, Seinda Pharmaceutical focuses on the
research and development, production, and sales of ophthalmic medical devices and new drugs.
Our
mission is to bring excellence and precision to ophthalmic in vitro diagnostics and
therapeutics by
developing improved choices for eye care.
Our Team
Together, our experienced leadership team has over 45 years of biomedical and pharmaceutical, business, and marketing experience, and the knowledge, skills, and expertise to guide Seinda to success.
Jing-Feng Huang, Ph.D.
Founder and Chief Executive Officer
Jing-Feng Huang, Ph.D.
Founder and Chief Executive Officer
Dr. Huang founded Seinda in 2015 with the vision of integrating immunology and
biomarker research in ophthalmic diseases and developing innovative point-of-care
(POC) in vitro diagnostic tests for eye disorders. She
has accumulated extensive knowledge from her research in T cell regulation and
pathological mechanism of immune diseases, and has published 30 research articles in
leading journals, including Science, J. Clin. Inv., J Exp. Med,
PNAS, Blood, Ophthalmology, IOVS. As an expert in ophthalmological
biomarkers and pathological mechanism research, Dr. Huang is well-recognized
internationally by experts in these fields.
With nearly 20 years of experience in innovative drug R&D and clinical development of multinational pharmaceutical companies, Dr. Huang has been engaged in the research and development of new drugs in the United States for more than ten years at Johnson & Johnson (J&J), for immune diseases such as lupus erythematosus, psoriasis, rheumatoid arthritis, asthma and allergies. Later, she joined Pfizer as Director of the Global Ophthalmic Clinical Development Department, during which she led multiple dry eye clinical trials and translational medicine research. From 2013 to 2017, Dr. Huang served as a special expert consultant of the National Eye Institute (NEI) to guide the plan design, implementation supervision, data analysis and report writing of a large multi-center dry eye clinical trial in the United States. Related dry eye clinical trial research results were published in the New England Journal of Medicine (NEJM).
Under Dr. Huang’s leadership, Seinda has developed a dry eye diagnostic reagent and conducted over 1,100 multi-center clinical trials throughout China. This reagent will soon be entering the industrialization and commercialization stage, with more rapid diagnostic products for ophthalmic diseases that fill the need for ophthalmic in vitro testing products soon to follow.
Dr. Huang obtained her PhD at The Scripps Research Institute (TSRI) in La Jolla, California and conducted her post-doctoral research in Immunology and Bioinformatics at J&J Pharmaceutical Research Institute.
With nearly 20 years of experience in innovative drug R&D and clinical development of multinational pharmaceutical companies, Dr. Huang has been engaged in the research and development of new drugs in the United States for more than ten years at Johnson & Johnson (J&J), for immune diseases such as lupus erythematosus, psoriasis, rheumatoid arthritis, asthma and allergies. Later, she joined Pfizer as Director of the Global Ophthalmic Clinical Development Department, during which she led multiple dry eye clinical trials and translational medicine research. From 2013 to 2017, Dr. Huang served as a special expert consultant of the National Eye Institute (NEI) to guide the plan design, implementation supervision, data analysis and report writing of a large multi-center dry eye clinical trial in the United States. Related dry eye clinical trial research results were published in the New England Journal of Medicine (NEJM).
Under Dr. Huang’s leadership, Seinda has developed a dry eye diagnostic reagent and conducted over 1,100 multi-center clinical trials throughout China. This reagent will soon be entering the industrialization and commercialization stage, with more rapid diagnostic products for ophthalmic diseases that fill the need for ophthalmic in vitro testing products soon to follow.
Dr. Huang obtained her PhD at The Scripps Research Institute (TSRI) in La Jolla, California and conducted her post-doctoral research in Immunology and Bioinformatics at J&J Pharmaceutical Research Institute.
Partner with Us
We are always seeking strategic partners for regional and/or global commercialization of our
products.
For more information, please email us info@seindabio.com.
SEINDA PHARMACEUTICAL CORPORATION
